 After NDA approval, the sponsor must review and report to the FDA every patient adverse drug experience it learns of.They must report unexpected serious and fatal adverse drug events within 15 days, and other events on a quarterly basis.The FDA also receives directly adverse drug event reports through its MedWatch program.